Encapsulated cell therapy - Rogosin Institute/Metromedia Bio-Science

Drug Profile

Encapsulated cell therapy - Rogosin Institute/Metromedia Bio-Science

Alternative Names: Cancer cell-containing agarose-agarose macrobeads; Cancer inhibitor macrobead - Metromedia Bio-Science; Macrobead biological anti-tumour therapy; Macrobead cancer therapy - Rogosin Institute; Macrobeads; Mouse renal adenocarcinoma cell-containing agarose-agarose macrobeads; Mouse renal carcinoma (RENCA) macrobeads; RENCA macrobeads

Latest Information Update: 10 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Rogosin Institute
  • Class Antineoplastics; Cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Colorectal cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 16 Aug 2015 Encapsulated cell therapy is still in phase II trials for Pancreatic cancer (Refractory metastatic disease) in the USA
  • 16 Aug 2015 Encapsulated cell therapy is still in phase II trials for Prostate cancer (Refractory metastatic disease) in the USA
  • 16 Aug 2015 Encapsulated cell therapy is still in phase II trials for Colorectal cancer (Refractory metastatic disease) in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top